OpGen Announces Expanded Adoption of Argus® Whole Genome Mapping System

Gaithersburg, Md. -- 11/19/12
Back To Press & Events

Major Genomics Sequencing Centers Worldwide Utilizing OpGen’s Whole Genome Mapping Technology

OpGen, Inc., a commercial stage DNA analysis company, today announced the Argus® Whole Genome Mapping System continues to gain broad adoption among genome sequencing centers worldwide. Five leading international genomic sequencing centers have joined the growing list of centers utilizing OpGen’s technology to enhance their next-generation sequencing capabilities. The centers include The Genome Institute at Washington University, St. Louis, MO; The Genome Analysis Centre (TGAC), Norwich, UK; Genoscope, Evry, France; National High-throughput DNA Sequencing Centre at the Centre for GeoGenetics, Copenhagen, Denmark; and Genome Institute of Singapore. These organizations join our growing customer base that includes Wellcome Trust Sanger Institute and BGI, public health and biodefense agencies, and research and service labs that are utilizing the company’s Whole Genome Mapping technologies and services.

“We adopted OpGen’s Argus System after evaluating the value of adding Whole Genome Mapping to improve whole genome sequences,” said George Weinstock, Ph.D., associate director of The Genome Institute at Washington University. “We combined Whole Genome Maps with sequence assemblies to correct errors and misassemblies in bacterial samples from the Human Microbiome Project, and now we are using the technology in larger genome projects.”

OpGen’s Argus Whole Genome Mapping System is the only commercially available technology that can provide a high resolution, complete visual map of a whole genome and individual chromosomes. OpGen’s unique single molecule analysis technology provides a whole genome view that compliments genome assembly and enables scientist to identify highly repetitive regions, tandem repeats and translocations that are very difficult to identify and clarify with sequencing alone. Sequencing projects can now be finished and validated with less investment in time, cost and computational effort.

“Our research focuses on a wide variety of projects from microbes to crop plants and mammals,” said Matthew Clark, Ph.D., sequencing technology development team leader at The Genome Analysis Centre. “Many of our projects are de novo assembly projects, where, without a closely related genome sequence, it can be difficult to critically assess the results. We often combine different sequencing technologies, and we are finding that regardless of the sequencing platform, error correction, or assembler used, OpGen’s Whole Genome Mapping identifies misassemblies and provides the highest quality de novo assembly for further research.”

“We are successfully expanding our customer base among major global sequencing centers,” said Douglas White, president and chief executive officer of OpGen. “By providing the highest quality, validated sequence assemblies, our goal is to enable translational research that will meet the highest standards for clinical applications.”

Share On Twitter Linkedin